Krystal Biotech, Inc. KRYS
New risk paragraphs, branching off last year
Each branch is a paragraph in Risk Factors with nothing like it in the 10-K filed Feb 19, 2025. A box jumps to the paragraph as filed, below.
Paragraphs with nothing like them in last year's 10-K
13 paragraphs in Risk Factors of the 10-K filed Feb 17, 2026 with nothing like them in the 10-K filed Feb 19, 2025. Quoted exactly. Paragraphs that were only edited are under 10-K change.
allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a partnering arrangement.
stricter labeling requirements for those product candidates that are approved, and a decrease in demand for any such product candidates.
changes include the elimination of the coverage gap phase and the replacement of the Coverage Gap Discount Program with the Manufacturer Discount Program, under which drug manufacturers are required provide a 10% discount for brand-name drugs and biologics during the initial coverage phase and a 20% discount during the catastrophic phase. Multiple pharmaceutical manufacturers have challenged the law in court, largely on constitutional grounds. To date, the majority of these challenges have been unsuccessful, with courts upholding the IRA. However, these suits will likely continue and the ultimate effects of such legal challenges are unclear. On April 15, 2025, President Trump issued an executive order directing the Secretary of the Department of Health and Human Services to take certain actions on drug pricing reform, including working with Congress on amendments to the IRA and rule making to establish new Medicare payment models for so-called “high-cost” prescription drugs and biological products. Subsequently, President Trump has issued additional executive orders directing additional actions designed to lower drug prices, including by tying the price of certain drugs to the price of those drugs in other countries. It is unclear whether the Trump administration executive orders will lead to actual legislative initiatives. At this time, we continue to evaluate the effect of the IRA and the Trump administration’s executive actions on our business operations and financial condition and results as the full impact of the IRA and the executive actions remains uncertain.
On July 4, 2025, legislation commonly referred to as the One Big Beautiful Bill Act was signed into law, which reduces funding to federal healthcare programs and imposes additional requirements to be eligible for healthcare, which may result in decreased access to healthcare, particularly in Medicaid programs.
formulary managers on the other. The ACA amended the intent requirement of the federal Anti-Kickback Statute to clarify that a person or entity does not have to have actual knowledge of this statute or specific intent to violate it;
•our operations in Europe and Japan may be directly or indirectly subject to European and Japanese law equivalents of each of the above U.S. federal laws, some of which may not have been applicable prior to the recent European Commission and MHLW approvals and commercial launch of VYJUVEK in Europe and Japan;
Show the other 7
In the United States, federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal information privacy laws, consumer protection laws, and other similar laws. Notably, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, imposes requirements on covered entities, as well as their business associates regarding the privacy, security, and transmission of individually identifiable health information.
misappropriation, loss or other unauthorized disclosure or use of confidential information of others, whether by us or a third-party, could: (i) subject us to civil and criminal penalties; (ii) have a negative impact on our reputation; or (iii) expose us to liability to third parties or government authorities.
There remains substantial uncertainty as to how the current U.S. administration will seek to or continue to modify or revise the requirements and policies of the FDA and other regulatory agencies with jurisdiction over VYJUVEK and our
European Commission, MHLW, or other foreign regulators may issue new or revised guidelines concerning the development and marketing authorization of gene therapy medicinal products.
We were granted RMAT designation for B-VEC from the FDA, and we may seek RMAT designation for some of our product candidates. In 2017, the FDA established the RMAT designation as part of its implementation of the 21st Century Cures Act to expedite review of any drug that meets the following criteria: it qualifies as a RMAT, which is defined as a cell
•identification of patients and the willingness of physicians to prescribe new therapies;
•our ability to continue to successfully sell VYJUVEK in the United States and internationally;
Paragraphs in the 10-Q filed Nov 2, 2026 that were not in the one before
New in the latest 10-Q
19 paragraphs in the 10-Q filed Nov 2, 2026 with nothing like them in the 10-Q filed Aug 3, 2026 (at least half the words must differ; new numbers alone do not count). Quoted exactly, grouped by the item heading above them. This is text that changed, not a judgement of how serious it is.
Financial statements and notes
The Company has received $ 3.0 million of insurance proceeds during the three and nine months ended September 30, 2026, related to reimbursement of litigation legal costs. The proceeds have been recorded as an offset to legal fees included in general and administrative expenses on the condensed consolidated statements of operations and comprehensive income and within operating activities on the condensed consolidated statements of cash flows.
Read in the 10-Q
In October 2026, the Company’s Board of Directors authorized the repurchase of up to $ 400 million of its common stock. The Company may repurchase shares of common stock from time to time through open market purchases, in privately negotiated transactions, or by other means. permitted under applicable securities laws, including through purchases compliant with Rule 10b-18 under the Exchange Act and trading plans adopted under Rule 10b5-1 under the Exchange Act. The program has no expiration date, does not obligate the Company to acquire any particular amount of common stock, and may be modified, suspended, or discontinued at any time at the Company’s discretion. The timing and amount of any repurchases will depend on a number of factors, including the market price of its common stock, general business and market conditions, liquidity and capital requirements, clinical development and commercialization plans, alternative uses of capital, and legal and regulatory requirements.
Read in the 10-Q
• the potential benefits of regulatory designations granted to our product candidates and our platform technology;
Read in the 10-Q
• our ability to execute any share repurchase program, including the timing, amount and funding of any repurchases and the potential impact of such repurchases on our liquidity and the trading price of our Common Stock.
Read in the 10-Q
KB113 is a redosable immunotherapy formulated for intratumoral injection and designed to drive sustained, localized expression of interleukin-2 (“IL-2”) and interleukin-12 (“IL-12”) in the tumor microenvironment and promote systemic immune-mediated tumor clearance, in development for the treatment of basal cell carcinomas (“BCCs”) in patients with GS. GS is a genetic disease characterized by a greatly increased risk of developing BCCs. Patients with GS can develop BCCs as early as infancy and may have hundreds of BCCs over their lifetimes requiring frequent and potentially disfiguring surgical procedures.
Read in the 10-Q
Show the other 14
In October 2026, we announced a positive clinical update from our pilot, multicenter, single-arm, open-label study evaluating intratumoral KB113 in the treatment of BCCs in patients with GS. In the three patient pilot study, more than 80% of assessed BCC lesions showed investigator-assessed clinical regression. Regression was observed in both injected and non-injected lesions, including substantial regression in lesions that were not directly injected with KB113, consistent with an abscopal effect. Histologic assessment also confirmed complete clearance of an injected BCC lesion in each patient.
Read in the 10-Q
We have initiated discussions with the FDA regarding the further clinical development of KB113 for the treatment of BCCs in patients with GS. We expect to provide an update on our development plans following alignment with the FDA.
Read in the 10-Q
Inhaled KB707 is a redosable immunotherapy formulated for delivery via inhalation and designed to drive sustained, localized expression of human IL-2 and IL-12 in the tumor microenvironment and promote systemic immune-mediated tumor clearance.
Read in the 10-Q
We are developing inhaled KB707 for the treatment of NSCLC based on preliminary evidence of antitumor activity from KYANITE-1, an open-label, multicenter, dose escalation and expansion Phase 1/2 study, evaluating inhaled KB707, as monotherapy or in combination, in patients with locally advanced or metastatic solid tumors of the lung.
Read in the 10-Q
• a decrease of $3.0 million resulting from insurance proceeds received as reimbursement of litigation legal costs previously incurred;
Read in the 10-Q
Income tax expense was $17.1 million for the three months ended September 30, 2026 and income tax benefit was $31.4 million for the three months ended September 30, 2025, respectively, which relates to state, federal and foreign income taxes. In the third quarter of 2025, we determined that it was more likely than not that the benefit from certain of our deferred tax assets will be realized. Accordingly, the related valuation allowance was released and a one-time benefit was recognized. See discussion in Note 10 of the notes to consolidated financial statements included in this Quarterly Report on Form 10-Q for more information.
Read in the 10-Q
• a decrease of $3.0 million resulting from insurance proceeds received as reimbursement of litigation legal costs previously incurred.
Read in the 10-Q
Income tax expense was $33.9 million for the nine months ended September 30, 2026 and income tax benefit was $15.1 million for the nine months ended September 30, 2025, which relates to state, federal and foreign income taxes. In the third quarter of 2025, we determined that it was more likely than not that the benefit from certain of our deferred tax assets will be realized. Accordingly, the related valuation allowance was released and a one-time benefit was recognized. See discussion in Note 10 of the notes to consolidated financial statements included in this Quarterly Report on Form 10-Q for more information.
Read in the 10-Q
In October 2026, our Board of Directors authorized the repurchase of up to $400 million of our common stock, exclusive of any applicable excise taxes, brokerage commissions, fees and other expenses incurred in connection with such repurchases. We may repurchase shares of our common stock from time to time through open market purchases, in privately negotiated transactions, or by other means permitted under applicable securities laws, including through purchases compliant with Rule 10b-18 under the Exchange Act and trading plans adopted under Rule 10b5-1 under the Exchange Act. The program has no expiration date, does not obligate us to acquire any particular amount of common stock, and may be modified, suspended, or discontinued at any time at our discretion. The timing and amount of any repurchases will depend on a number of factors, including the market price of our common stock, general business and market conditions, our liquidity and capital requirements, our clinical development and commercialization plans, alternative uses of capital, and legal and regulatory requirements.
Read in the 10-Q
Risk Factors
Our stock repurchase program may not be fully consummated or enhance long-term stockholder value, and repurchases could affect the price of our common stock, increase its volatility, and diminish our cash reserves.
Read in the 10-Q
In October 2026, our Board of Directors authorized the repurchase of up to $400 million of our common stock, exclusive of any applicable excise taxes, brokerage commissions, fees and other expenses incurred in connection with such repurchases. We may repurchase shares of our common stock from time to time through open market purchases, in privately negotiated transactions, or by other means permitted under applicable securities laws, including through purchases compliant with Rule 10b-18 under the Exchange Act and trading plans adopted under Rule 10b5-1 under the Exchange Act. The program has no expiration date, does not obligate us to acquire any particular amount of common stock, and may be modified, suspended, or discontinued at any time at our discretion. The timing and amount of any repurchases will depend on a number of factors, including the market price of our common stock, general business and market conditions, our liquidity and capital requirements, our clinical development and commercialization plans, alternative uses of capital, and legal and regulatory requirements. Repurchases could affect the price of our common stock and increase its volatility, and the existence of the program could cause the price of our common stock to be higher than it would be in its absence and could reduce the market liquidity for our common stock. In addition, repurchases could also reduce the cash available to fund our clinical programs, the commercialization of VYJUVEK, potential business development transactions, and other corporate purposes, and may be subject to a 1% U.S. federal excise tax. There can be no assurance that the program will be fully consummated or enhance long-term stockholder value, and the market price of our common stock may decline below the prices at which we repurchased shares. Any failure to make repurchases after we have announced an intention to do so, or any suspension or discontinuation of the program, could adversely affect the price of our common stock.
Read in the 10-Q
Other information
On August 31, 2026, Kathryn Romano, our Executive Vice President & Chief Accounting Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act for the sale of up to 11,527 shares of our common stock (including up to 10,927 shares to be acquired upon the exercise of vested stock options), the exercise of vested stock options for up to 1,573 shares of our common stock to be held by Ms. Romano, and a charitable gift of up to 1,163 shares of our common stock, in each case subject to certain conditions. The trading arrangement will terminate on December 31, 2027, subject to early termination in accordance with its terms, including upon the completion of all transactions contemplated by the trading arrangement.
Read in the 10-Q
On September 10, 2026, Laurent Goux, our Executive Vice President, Head of International, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act for the sale of up to 3,045 shares of our common stock to be acquired upon the exercise of vested stock options, subject to certain conditions. The trading arrangement will terminate on September 10, 2027, subject to early termination in accordance with its terms, including upon the completion of the sale of all of the shares of our common stock subject to the trading arrangement.
Read in the 10-Q
Item 6
** Furnished herewith and not “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.
Read in the 10-Q
The 10-Q's risk factors against the 10-K
Item 1A of the 10-Q filed Nov 2, 2026 against Item 1A of the 10-K filed Feb 17, 2026.
A 10-Q repeats only the risks that changed, so a 10-K paragraph that is missing from it is not counted as removed.
Added is a paragraph with nothing like it in the 10-K, Reworded a sentence that is in both with several words changed,
Quiet changes a sentence in both where one to four words changed and one is a hedge or a modal
(cut words struck through, new words highlighted).
Text on the page, not a score; each links to the filing at sec.gov.
Phrases used for the first time
Two-word phrases in Risk Factors of the 10-K filed Feb 17, 2026 that are in none of the 1 earlier 10-Ks stored, back to Feb 19, 2025
Where each one is used
- foreign regulators: In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or regulators in other...
- commission mhlw: The clinical trial requirements of the FDA, EMA, European Commission, MHLW, and other regulatory authorities and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use, and market of such product...
- union japan: Privacy and data security have become significant areas of legal and regulatory focus in the United States, European Union, Japan, and in many other jurisdictions where we conduct or may conduct our operations. In our ordinary course of business, we collect, receive, store, process, generate, use, transfer,...
- applicable regulators: In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or regulators in other...
- president trump: changes include the elimination of the coverage gap phase and the replacement of the Coverage Gap Discount Program with the Manufacturer Discount Program, under which drug manufacturers are required provide a 10% discount for brand-name drugs and biologics during the initial coverage phase and a 20% discount during...
- executive orders: changes include the elimination of the coverage gap phase and the replacement of the Coverage Gap Discount Program with the Manufacturer Discount Program, under which drug manufacturers are required provide a 10% discount for brand-name drugs and biologics during the initial coverage phase and a 20% discount during...
- executive actions: changes include the elimination of the coverage gap phase and the replacement of the Coverage Gap Discount Program with the Manufacturer Discount Program, under which drug manufacturers are required provide a 10% discount for brand-name drugs and biologics during the initial coverage phase and a 20% discount during...
- granted marketing: On April 23, 2025, the European Commission granted marketing authorization to VYJUVEK, and we commercially launched VYJUVEK in Germany in August 2025. On July 24, 2025, Japan’s MHLW granted marketing authorization to VYJUVEK, and we commercially launched in Japan in October 2025. We currently have operations and...
Used at least twice, small words left out. Counted, not picked: a phrase can be new because the company renamed something.
What was taken out
19 paragraphs of last year's Risk Factors with nothing like them now. The longest are quoted.
Sources
Item 1A of each 10-K and 10-Q on EDGAR, quoted exactly. Each paragraph links to the filing at sec.gov.
Also
10-K change: what was reworded or cut, section by section.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/KRYS/export.csv") into a cell.